share_log

Alliance Global Partners Maintains Buy on Vivos Therapeutics, Lowers Price Target to $6

Alliance Global Partners Maintains Buy on Vivos Therapeutics, Lowers Price Target to $6

Alliance global partners維持對vivos therapeutics的買入評級,將目標價下調至6美元
Benzinga ·  2024/11/20 00:58  · 評級/大行評級

Alliance Global Partners analyst Scott Henry maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and lowers the price target from $8.25 to $6.

Alliance Global Partners的分析師Scott Henry維持對Vivos Therapeutics(納斯達克:VVOS)的買入評級,並將價格目標從8.25美元下調至6美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論